BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that the Epic Hygiene dental laser meets recent guidance from the Center for Disease Control (CDC), which recommends not using ultrasonic scalers to prevent the transmission of COVID-19. Ultrasonic scalers create a visible water spray that can contain particle droplets of water, saliva, blood, microorganisms, and other debris, which can serve as a conduit to spread the virus.
As dental offices in all 50 states begin to open their doors, they can rely on the Epic Hygiene laser for Laser Bacterial Reduction (LBR) therapy, which was cleared by the Food and Drug Administration (FDA) in March. This indication allows hygienists to perform gentler, highly effective treatments for bacterial reduction and managing periodontal disease without using water.
"We have already seen how all-tissue Waterlase dental lasers create 98% less aerosol than traditional dental handpieces, meeting the American Dental Association's recommendation of reduced aerosol production to limit the spread of COVID-19," said Todd Norbe, CEO of BIOLASE. "We are proud that we have continued to see our products, like the Epic Hygiene laser, meet the unique needs of dentists during this time. We believe this aligns directly with our mission of advancing dentistry, beyond the pandemic, to treat patients in the safest way possible."
Epic Hygiene is the latest innovation in proven Epic laser technology, designed by dental hygienists for dental hygienists. This new laser system gives dental professionals a total solution to effectively manage non-surgical periodontitis and increase clinical production. The system includes proven step-by-step clinical protocols, including pocket therapy and perio debridement, for easy implementation.
To learn more about the Epic Hygiene laser, please visit biolase.com/epichygiene.
About BIOLASE, Inc.
BIOLASE, Inc. is a medical device company that is a global market leader in the manufacturing and marketing of proprietary dental laser systems that enable dentists and dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and surgical applications. BIOLASE's laser systems are designed to provide clinically superior, patient-friendly results for many types of common dental procedures compared to those achieved with traditional instruments. BIOLASE has sold over 41,000 laser systems to date in over 80 countries around the world.
For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, LinkedIn at www.linkedin.com/company/biolase, Instagram at www.instagram.com/waterlase_laserdentistry, and YouTube at www.youtube.com/biolasevideos.
BIOLASE®, Waterlase®, Waterlase iPlus® and Epic Hygiene™ are registered trademarks of BIOLASE, Inc.
To support COVID-19 demands and deliver an entirely new digital approach for emergency patient engagement, Awrel, a dental software solutions innovator, unveiled its new Emergency Dental Virtual Assistant. The turnkey chatbot, deployed by embedding a single snippet of code into an existing website, uses artificial intelligence (AI) to empower remote triage and management of dental emergencies.
This first-of-its-kind solution gives patients 24x7 access to screening and question-answering tools designed to collect relevant information and provide clinically vetted recommendations for next-step actions (self-care, appointment scheduling, etc.) Dental providers receive chatbot notifications via HIPAA-compliant text messaging. Follow-up patient communication is done via phone or Awrel’s HIPAA-compliant texting application. Data exchanged via the Awrel chatbot and texting applications can be readily transferred to the patient’s dental record.
“This is the way of the future, the new normal,” said Alan Farber, DDS. “Healthcare has seen major advances in digital patient engagement, yet HIPAA compliance has remained a challenge. Today, COVID requires dentists to reinvent themselves. Awrel’s solutions provide a secure and cost-effective way to meet unprecedented demands for remote caregiving. It’s a win-win for practices and patients.”
The bot is live at the site of Farber Center for Periodontics, https://longislandperio.com/contact/
While Dr. Farber initially deployed the chatbot to better meet existing customer needs, he and his colleagues were pleased to discover that it has generated several new patients. They have used Awrel’s virtual assistant since February to support their two New York-based practice locations.
According to Dr. Farber, 24x7 access to the screening tool allows patients to exchange information at a time and place that’s convenient to them. “Customer service is key in the new world of healthcare – and this approach is rock solid. Some patients are more willing to share information with a bot rather than with a live human, and to do so in a timelier fashion. Early intervention can enhance patient experience, improve treatment outcomes, and reduce treatment time.”
“From the start of this pandemic, we worked diligently to develop a solution that immediately supports dental providers seeking an efficient way to triage patients and answer questions while also addressing social distancing needs of staff and patients,” said Awrel Founder and CEO Arnold Rosen, DDS. “Awrel’s offerings are unlike others because they can easily be adapted to work seamlessly across the internet, mobile devices and smart speakers, and can readily integrate with existing tele-dental services.”
The Farber Center for Periodontics and Dental Implants is among the earliest adopters of Awrel’s chatbot. “The inherent value of virtual experiences is obvious,” Dr. Farber stated. “Patients and staff can better protect themselves against COVID. As an added benefit, our practice has saved valuable time and money by automating once-manual processes for emergency access and assessment.”
Dr. Farber learned about Awrel’s new chatbot during a webinar presented by the International Association of Dental Specialists, an organization he founded. Colleagues responded positively to this new technology, he stated. “Awrel’s tools are very well structured and have worked flawlessly for our practice. I see the use of chatbots as a benefit to any dentist.”
Boston-based Awrel, a dental software solution provider, delivers out-of-the-box and custom virtual assistants using conversational experiences and artificial intelligence to automate and document workflow, improve outcomes, reduce costs and enhance the patient and clinician experience. Awrel launched dentistry’s first HIPAA-compliant desktop and mobile texting application in 2016 and offers Awrel Voice™, a virtual assistant used on devices such as Amazon Echo or Google Home for hands-free lab ordering and other workflows. Each day, Awrel solutions facilitate thousands of data exchanges, including image, text and document sharing, individual and group messaging, collaborative transactions (ordering of custom prostheses, supplies and equipment, etc.) and cloud archiving. Dental solution providers enhance their offerings with Awrel via capabilities to define unique workflows, create product- and customer-specific applications, and private label the company’s solutions. https://awrel.com
The annual rundown of the dental profession’s heaviest hitters as presented by Incisal Edge magazine has never been more fraught—because the industry has never faced anything quite like the pandemic. How have these top players achieved their current status—and where are they, and dentistry itself, headed in the months and years ahead?
The 32 individuals—one for every adult tooth—have some ideas. And they’re well-placed to implement them. Not all of them are focused on Covid-19 to the exclusion of all else, of course, but the virus and its attendant maladies, physiological and economic alike, is at the fore of everyone’s mind. And the esteemed power players you’ll read about in the summer edition will certainly be a part of the recovery.
"Four years ago, when we began tracking dentistry's most influential people, we didn't envision how a pandemic could shock all of dentistry, or how quickly the industry would begin adapting," said Incisal Edge Founder Chuck Cohen. "But here we are, and identifying who's leading the conversation right now—and positioned to drive change—is vital in a world where the rules of influence and authority are shifting faster than ever and effective thought leadership more often propels people to positions of influence."
The 32 Most Influential People in Dentistry for 2020, ranked by Incisal Edge include:
1. Eric Wenzel, Director, Oral Care Global Business, 3M Minneapolis, Minnesota
2. Joseph Hogan, Director, President and CEO, Align Technology San Jose, California
3. Casey Hannan, Director, Division of Oral Health, CDC National Center for Chronic Disease Prevention and Health Promotion Atlanta, Georgia
4. Stanley Bergman, Chairman and CEO, Henry Schein Melville, New York
5. Lawmakers – dentists in the U.S. House of Representatives, Washington, D.C. : Brian Babin (R-TX), Drew Ferguson (R-GA), Paul Gosar (R-WY), Mike Simpson (R-ID) Jeff Van Drew (R-NJ)
6. Don Casey, CEO, Dentsply Sirona Columbus, Ohio
7. Roshan Parikh, Head of Dentistry, Walmart U.S. Health & Wellness Atlanta, Georgia
8. Howard Farran, Founder, Dentaltown.Com, Dentaltown Magazine Phoenix, Arizona
9. Kathleen O’Loughlin, Executive Director, ADA Chicago, Illinois
Michael Graham, Senior VP, Government and Public Affairs, ADA Washington, D.C.
Marko Vujicic, Chief Economist & Vice President, ADA Health Policy Institute Chicago, Illinois
10. The Entrepreneurial Dentist, Business-Minded, Pandemic-Nervous Everytown, USA
11. Karen West, President, American Dental Education Association, Washington, D.C.
12. Rick Workman, Founder and Executive Chairman, Heartland Dental Effingham, Illinois
Robert Fontana, CEO, Aspen Dental, East Syracuse, New York
Steve Thorne, Irvine, California
13. Michael Apa, Cosmetic Dentist, Apa Aesthetic New York, New York; Los Angeles, California; Dubai, United Arab Emirates
14. Michael Cohen, Founder, Seattle Study Club Seattle, Washington
Frank Spear, Founder & Director, Spear Education Phoenix, Arizona; Seattle, Washington
15. Amir Aghdaei, CEO, Envista Holdings Brea, California
16. Gordon Christensen, Founder and CEO, Practical Clinical Courses Provo, Utah
John Kois, Founder and Director, The Kois Center Seattle, Washington
17. Douglas Erickson, CEO, Facility Guidelines Institute St. Louis, Missouri
18. Michael Castro, CEO, Delta Dental Oak Brook, Illinois
19. Michelle Lee, Executive Director, Organization for Safety Asepsis and Prevention Atlanta, Georgia
20. Richard Schnall, Managing Partner, Clayton Dubilier & Rice Healthcare Practice New York, New York
21. Ann Battrell, Executive Director, American Dental Hygienists’ Association Chicago, Illinois
22. Wardah Inam, CEO, Overjet Cambridge, Massachusetts
23. Greg Minzenmayer, Chief Operating Officer, Glidewell Laboratories Newport Beach, California
24. Paul Goodman, Founder, Dental Nachos Philadelphia, Pennsylvania
25. Guillaume Daniellot, CEO, Straumann Basel, Switzerland
26. Jerome Adams, 20th Surgeon General of The United States Washington, D.C.
27. Anton Woolf, CEO, Argen San Diego, California
28. Jeff Johnson, Senior Research Analyst, Medical Technology Robert W. Baird & Company Milwaukee, Wisconsin
29. Mark Adams, Dental Business Leader, Amazon Seattle, Washington
30. Mike Cataldo, CEO, Convergent Dental Needham, Massachusetts
31. Scott Leune, Founder, Breakaway Practice San Antonio, Texas
32. Dave Sproat, CEO, Young Innovations Algonquin, Illinois
Jim Harding, CEO, Henry Schein
Laura Kelly, CEO, Microdental Laboratories And Modern Dental Usa
Diego Gabathuler, Ceo, Ivoclar Vivadent
Jay Geier, CEO, The Scheduling Institute
Steve Bishop, CEO, Procter & Gamble Health Care
Justin Joffe & Hitesh Tolani, CEO, Henry The Dentist; Founder And Ceo, Virtudent
Ones to Watch
Christopher E. Steele, President, Park Dental
Jonathan Koch, Senior Vice President and CEO, Global Dental Group, Henry Schein
Kenneth Serota & Ron Saslow, President of Dental, Cantel Medical; CEO, Hu-Friedy
Browse the complete Summer 2020 digital edition here, or go directly to the feature here. For additional information regarding the magazine, visit: http://www.incisaledgemagazine.com/
About Incisal Edge
Knowledge. Success. Life. Those three words, printed on the cover of every issue, guide editorial content for Incisal Edge magazine. Published by Benco Dental since 1997, Incisal Edge is focued on helping readers get an edge—and keep it—in the fast-changing worlds of healthcare and business. Known for its “40 Under 40 — America’s Best Young Dentists,” which highlights the country’s brightest rising stars, the magazine’s content includes “The 32 Most Influential People in Dentistry," plus columns and features packed with sharp advice, expert success tips on everything from marketing to operations, and the latest clinical advances and essential tools for practicing and living smarter. Incisal Edge magazine’s print edition reaches 130,000 readers quarterly via a direct mail distribution package with Dentaltown magazine. Digitally, incisaledgemagazine.com, leads with dynamic visuals and follows with exclusive web content, an improved mobile experience, and a centralized nomination hub for the magazine’s signature awards: the aforementioned 40 Under 40, the Lucy Hobbs Project Awards for Exemplary Women in Dentistry and the Incisal Edge Design Competition for interior design, architecture and space planning within the dental profession.
About Benco Dental
Benco Dental is Driving Dentistry ForwardSM with innovative solutions and our caring family culture. Our industry firsts include Painless® electronic ordering, automated supply management, BluChip® customer loyalty rewards, CenterPoint design/equipment superstores and OneVisitTM open architecture CAD/CAM. Independent since 1930, our over 1,500 dedicated associates serve customers at locations nationwide including 400+ sales representatives and 300+ factory-trained service technicians. Benco Dental is one of Fortune's Best Workplaces in Health Care and Biopharma and among Pennsylvania Best Places to Work® for 12 of 15 prior years.
Nationwide survey of over 275 consumers reveals seeing their dentist after COVID-19 lockdown is more important than getting a haircut
The survey results also identify key drivers and barriers that impact their decisions to resume dental care visits
Lanmark360, a full-service healthcare agency with deep experience in the dental space announces the immediate availability of key consumer insights regarding their desire to see their dentists for a checkup as COVID-19 restrictions are lifted in their state or local municipality.
As indicated by the survey results, consumer sentiment, perceptions and attitudes are quite positive with respect to their willingness to rapidly return to dental practices. When asked, “Is being able to return to the dentist more or less important than other things?”, respondents ranked seeing their dentist as more important than getting their hair cut, pet grooming and going to restaurants.
“We found that over half of the respondents fell behind on their dental care due to canceled appointments during the COVID-19 pandemic,” states Howard Klein, Lanmark360 President. “However, 10% intend to see their dentists immediately once their dentist’s office has reopened, and a full 50% intend to return to their dentist for a routine cleaning within three months.”
The majority of respondents surveyed also indicate a preference for single-visit dentistry, and more than 50% believe practice safety protocols are extremely important.
Many other important insights are highlighted in the full survey results report, including crucial information that dentists can leverage to help ensure patients feel safe upon their return to the dental office, as well as how patients prefer to be contacted by their dentist’s office once they reopen and what information they expect to receive.
To download the full report, click here.
Largent Health, LLC announced today a new FDA clearance to market the novel FiteBac® Antimicrobial Cavity Cleanser, with 2% K21. Dental cavity cleansers are used for cleansing and moistening/re-wetting of prepared dental surfaces prior to completion of tooth restoration. The company included in their FDA application, compelling data supporting antimicrobial activity that reduces dentally relevant microbes.
FiteBac® technology exemplifies the marriage of antimicrobial technology to material science, enabling the manufacture of modern materials offering sustained, non-leaching antimicrobial protection across a broad range of products. “The FDA clearance of FiteBac® Antimicrobial Cavity Cleanser represents the 2nd successful FDA regulatory clearance of our FiteBac® technology this year,” said John W. Sharkey, Ph.D., CEO of Largent Health, LLC. “This further validates our unique FiteBac® technology and its potential in the development of additional medical products with durable antimicrobial technology built-in.”
FiteBac® Antimicrobial Cavity Cleanser, with 2% K21, is intended to become part of the restoration/dentin interface by copolymerizing with the dental adhesive. Research shows FiteBac® Cavity Cleanser can not only help remove debris in carious lesion preparations but also help reduce the presence of dentally relevant organisms within the prepared tooth structure and to penetrate exposed dentin tubules, allowing restorative adhesives to tightly bind to the prepared dentin surface.
“With receipt of FDA clearance in hand, we look forward to implementing production scale-up and pre-launch activities over the coming weeks,” said Jude Dinges, Chief Commercial Officer at Largent Health. “With the introduction of FiteBac® Antimicrobial Cavity Cleanser, we can now offer dentists a differentiated product to both help the dental professional ensure the restoration site is clear of carious debris and assist in addressing residual microbial contamination within the restoration site."
To learn more about how FiteBac® technology is being developed for medical applications please visit www.LargentHealth.com
About Largent Health LLC
Largent Health, LLC, based in Marietta, GA, is a private company dedicated to the research, development and commercialization of innovative healthcare products incorporating FiteBac® technology, a superior approach to antimicrobial protection. To learn more please visit www.LargentHealth.com.
SAN JOSE, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- Align Technology, Inc. (Nasdaq: ALGN) today announced the award of nine research grants under the company’s eleventh Annual Research Award Program. The global interest in research of dental and orthodontic treatment continues to grow as evidenced by the increasing number of applications Align Technology receives each year from universities around the world.
“Through the academic research community, we continue to validate the clinical efficacy and benefits of clear aligner therapy with the Invisalign system in general dentistry and orthodontic treatments,” said Raj Pudipeddi, Align Technology chief innovation, product, and marketing officer and senior vice president. “These science and research findings help further our ongoing commitment to product innovation that transforms smiles and changes lives for millions of people around the world through our network of Invisalign-trained doctors.”
The Americas research award recipients for 2020 are:
University of Alberta (Edmonton, Canada) – Primary Investigator, Dr. Tarek El-Bialy
University of Toronto (Toronto, Canada) – Primary Investigator, Dr. Siew-Ging Gong
Jacksonville University (Jacksonville, USA) – Primary Investigator, Dr. Tabaa Sawsan
University of Washington (Seattle, USA) – Primary Investigator, Dr. Greg J. Huang
The European research award recipients for 2020 are:
National Kapodistrian University of Athens (Athens, Greece) – Dr. Iosif Sifakakis
University of Campania (Naples, Italy) – Primary Investigator, Dr. Letizia Perillo
University of Rome “Tor Vergata” (Rome, Italy) – Primary Investigator, Dr. Roberta Lione
University of Turin (Turin, Italy) – Primary Investigator, Dr. Bruni Alessandro
The Asia Pacific research award recipient for 2020 is:
Stomatology Hospital of Xi’an Jiaotong University (Shaanxi, China) – Primary Investigator, Dr. Yu-cheng Guo
The funded research studies cover a wide range of topics for projects seeking to better understand treatment in orthodontics and dentistry including:
effects of orthodontic appliances on the active oral microflora,
Invisalign treatment in adult anterior open bite patients,
3D changes in the nasal airway after maxillary arch expansion,
temperature conductivity to the tooth surfaces due to light-curing during bonding,
Invisalign First™ treatment on the transverse dimension,
evaluating palatal volume and surface area measurements between two appliances,
the effect of aligner wear time on gingival crevicular fluid,
evaluating a light-curing appliance that will reduce chairside time, and
determination of the stability of the palatal rugae in non-extraction cases, especially in the cases with molar distalization.
All award applications received were first reviewed and prioritized in a blind evaluation by an independent academic committee. The final recipients were then determined by Align Technology.
About Align Technology, Inc.
Align Technology designs and manufactures the Invisalign® system, the most advanced clear aligner system in the world, iTero® intraoral scanners and services, and CAD/CAM software. Align has helped treat over 8 million patients with the Invisalign system and is driving the evolution in digital dentistry with the iTero intraoral scanner and exocad CAD/CAM software − modernizing today’s practices by enabling enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies. Visit www.aligntech.com for more information.
For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com.
“We’ve been working with XJet NanoParticle Jetting technology for some time. Up to now it has been used for developing product iterations and providing proof of concept,” says Straumann VP Stephan Oehler. “Now we’re scoring the first product development project to reach the next level of bringing this technology to production of ceramic end-use parts. We believe this technology can scale up for production effectively; there’s a large print bed and with the soluble support material, we find post-processing simple and efficient.”
Recognized as a leading innovator enhancing the standards of dental patient care, Straumann was an early adopter of ceramic additive manufacturing as one of the first companies to invest in XJet NPJ technology. According to Oehler, Straumann was won over by the technology because of the accuracy of parts, shorter overall production cycles, and the game-changing soluble support material that allows unique ease-of-use.
“We work with ceramic in a lot of our products, so when we learned there was a new technology in the field, we looked into it. XJet convinced us with the quality of parts, the fine details and accuracy. In addition to that, the density of the material is extremely high, close to 100%, so it’s not like working with an ‘AM material.' We’re well-versed with the benefits of AM, so we knew that the freedom of design and complex geometries delivered by the technology, now for ceramic materials, could open up new product and application possibilities for the business,” states Philippe Chavanne, Head New Technology Competence Center, adding, “We were very impressed with the outstanding dedication and support provided by the XJet team, particularly Avi Cohen, Vice President, Healthcare and Education, who supported us in this collaboration from the very first moment.”
Headquartered in Basel, Switzerland, Straumann Group develops, manufactures, and supplies dental implants, instruments, biomaterials, CADCAM prosthetics, digital equipment, software, and clear aligners for applications in replacement, restorative, orthodontic, and preventive dentistry. Despite the COVID-19 pandemic, Straumann has been able to keep its XJet Carmel 1400 AM System running throughout.
“There’s already a demand for the ceramic parts produced on the Carmel 1400, and social distancing is viable because operation of the system is very simple, so we’ve been able to keep the system running even through the global pandemic,” states Oehler.
“It’s incredible working with global leaders such as Straumann who are passionate and innovative about the products and services they provide. Working with them to move into production parts is hugely motivating and we’re delighted to see our partnership go from strength to strength,” enthuses XJet CBO Dror Danai.
As the global battle to understand and eliminate the coronavirus continues, a new study published in the Journal of Dental Research demonstrates that testing of oropharyngeal secretions (OS) may reduce the number of false negative results from nasal swab testing of patients who have seemingly recovered from the disease.
In the study, led by Jingzhi Ma, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Department of Stomatology, Wuhan, China, a small number of patients that had tested negative through nasopharyngeal swabs were found to be positive through the testing of oropharyngeal secretions.
The first prospective study of its kind included 75 ready-for-discharge COVID-19 patients who tested negative using two consecutive nucleic acid amplification testing (NAAT) of viral samples retrieved with nasopharyngeal swabs (NPS).
Because of detection of potential false-negatives in that cohort, NAAT results of paired OS and NPS samples collected from 50 additional COVID-19 recruits during their recovery stage were used in a second prospective study to compare the diagnostic values of the two viral RNA sampling methods.
Oropharyngeal secretions obtained from 2 of the 75 subjects in the first study yielded positive results for SARS-CoV-2 nucleic acid. In the second study, OS samples were significantly more sensitive for detection of the virus that NPS samples and missed only 14% of positive cases compared with 59% for the NPS samples.
Sampling of OS is a simple procedure that can be performed in any quarantine setting and minimizes contact between healthcare workers and patients, thereby reducing the risk of virus transmission.
“The NPS test has a risk of sending home more patients who still have the infection while the OS test will make such errors in fewer patients. Although OS sampling improves the accuracy of SARS-CoV-2 nucleic acid testing, it must be emphasized that this conclusion is based on a very small sample size,” stated Ma.
About the Journal of Dental Research
The IADR/AADR Journal of Dental Research (JDR) is a multidisciplinary journal dedicated to the dissemination of new knowledge in all sciences relevant to dentistry and the oral cavity and associated structures in health and disease. The JDR continues to rank #3 in Impact Factor of 91 journals, #2 without self-citations, as well as #2 of 91 in Article Influence with a score of 1.627. The JDR’s 5-year Impact Factor remained above 5 for the fifth year at 5.844 — ranking #2 of 91 journals. With over 20,000 citations, the JDR also boasts the most citations in the “Dentistry, Oral Surgery & Medicine” category, over 3,500 citations above the 2nd ranked journal in the field.
International Association for Dental Research
The International Association for Dental Research (IADR) is a nonprofit organization with over 10,000 individual members worldwide, with a Mission to drive dental, oral and craniofacial research to advance health and well-being worldwide. To learn more, visit www.iadr.org. The American Association for Dental Research (AADR) is the largest Division of IADR with 3,100 members in the United States. To learn more, visit www.iadr.org/aadr.
Structo, a NUS-born 3D printing startup, has begun manufacturing 3D printed nasopharyngeal (NP) testing swabs in Singapore to help in the fight against the COVID-19 global pandemic.
Working in collaboration with authorities and healthcare professionals in Singapore, the company has now produced a million 3D printed NP testing swabs, with deliveries to customers in Singapore starting this week. Each of the swabs are individually sterilized and packaged before being delivered. Structo is scaling up rapidly to fulfil orders from healthcare institutions and other key parties across Singapore as well as customers globally and will soon have the capability to produce over 1 million 3D printed nasal testing swabs per week.
Structo is a 3D printing startup which operates primarily in the dental industry. Since the start of the pandemic, working in collaboration with other 3D printing partners, universities, and medical institutions across Singapore, Structo has mobilized its resources towards the manufacturing of pre-sterilized nasopharyngeal (NP) swabs, thereby enabling more COVID-19 testing to take place across the region.
There are limited numbers of testing kits currently in circulation globally, and with many countries now easing their lockdown restrictions, there is an urgent need for testing on a massive scale in order to fight the virus, particularly in heavily stricken countries such as US, Brazil, and Russia. Whilst Singapore has deployed effective contact tracing mechanisms to curb the spread of the virus, continued large scale testing is seen as critical in allowing it to return to a state of normality.
Structo’s 3D printed NP testing swabs are FDA registered medical devices, which adhere to strict manufacturing guidelines. The Structo team manufactures its swabs in accordance with Struco’s ISO 13485 QMS requirements from biocompatible material and sterilizes each individually packed swab to ISO 11135 standards.
“We have been in touch with the authorities in Singapore for several months working with doctors and hospitals to validate a number of different designs and to ensure that all the nasal swabs that we manufacture will be safe for final use on patients,” said Huub van Esbroeck, Founder of Structo.
“In this climate, we recognize the importance of the availability of testing kits and the strain that the COVID-19 pandemic has placed on the economy and supply chains worldwide,” said Huub van Esbroeck. "We hope that our in-house manufacturing capabilities will be able to help alleviate some of those problems and help us avoid a shortage of critical testing equipment globally."
Seasoned deep tech investor and Structo backer Wavemaker Partners believes that deep tech startups are uniquely positioned to add tremendous value in these uncertain times. “Structo’s proprietary high-speed 3D printing technology paired with their expertise in manufacturing medical devices allowed them to react quickly to this pandemic. They went from producing dental models one day to nasopharyngeal swabs the next without the need for retooling,” said Paul Santos, Wavemaker Partners' managing partner, based in Singapore. “The team is now working round-the-clock on ramping up production capacity in the coming weeks as we anticipate more interest from around the world.”
With a consolidated effort from both the government and the private sector, Singapore is in a great position to spearhead this initiative. “In today’s climate, it’s imperative that we come together to offer our expertise and resources and help in the fight against COVID-19,” Huub adds. “We look forward to collaborating with government agencies and healthcare institutions globally to utilize our manufacturing resources and help those who need them the most.”
Microbrush, a leading US-based global manufacturer and supplier of flocked applicators, has launched a nasopharyngeal test swab to meet the growing demand for COVID-19 testing requirements.
Sterilized and individually packaged in a medical-grade pouch, the Microbrush Test Swabs are ready-for-use intended for clinical nasopharyngeal sample collection. Manufactured in Grafton, Wis., Microbrush Test Swabs are a natural product line extension, following a 30-year track record of US-manufactured applicators for the healthcare industry. Flocked with soft nylon fibers, the Microbrush Test Swab provides an improved patient experience over 3D-printed swabs.
“Microbrush has rich manufacturing expertise in this category with over 10 billion flocked applicators produced since 1991,” said Dave Sproat, CEO of Young Innovations, Inc. “With healthcare providers in great need of COVID-19 test supplies, we’re incredibly proud to do our part in supporting this critical need by bringing a significant increase in production capacity to the market right away.”
“We were uniquely positioned to develop and manufacture this product quickly due to our strict adherence to quality as an FDA-registered facility; our deep-rooted experience in flocked applicator technology; and very strong, supportive partners,” added John Frymark, Vice President of Product Development at Young Innovations. “Developed in collaboration with several leading institutions and corporations. This product launch was a true team effort and a great testament of leading businesses operating with a high sense of urgency around an immediate healthcare need.”
The Microbrush Test Swab is FDA-listed and ready for immediate purchase. For more information on how to order Microbrush Test Swabs, please contact: Dave Newman email@example.com
Microbrush is a subsidiary of Young Innovations, Inc., a portfolio company of The Jordan Company.
About Young Innovations, Inc.
Young Innovations (www.younginnovations.com) is a leading global provider of supplies and equipment used by dentists, hygienists, dental assistants and consumers. Our portfolio of brands includes products that hold leadership positions in the preventive, restorative, orthodontic and endodontic segments. With its mission of Creating Smiles, Creating Possibilities, Young focuses on delivering innovative, high-quality products and solutions to clinicians and their patients. We continue to enhance our portfolio of brands and products through organic growth and acquisitions.
About The Jordan Company
The Jordan Company founded in 1982, is a middle-market private equity firm that manages funds with original capital commitments in excess of $11 billion. TJC has a 38-year track record of investing in and contributing to the growth of many businesses across a wide range of industries including Industrials, Transportation & Logistics, Healthcare & Consumer and Technology, Telecom & Utility. The senior investment team has been investing together for over 20 years and is supported by the Operations Management Group, which was established in 1988 to initiate and support operational improvements in portfolio companies. Headquartered in New York City, TJC also has an office in Chicago.